To compare the pharmacokinetics of gentamicin in infants receiving high-frequency oscillatory ventilation (HFOV) with infants receiving conventional mechanical ventilation.
INTRODUCTION
Mechanical ventilation has greatly improved the survival of infants with pulmonary failure. However, barotrauma and high-oxygen requirements during such events are associated with complications such as bronchopulmonary dysplasia and chronic lung disease. 1 High-frequency oscillatory ventilation (HFOV), which delivers small amounts of gas at rapid rates, is an alternative to conventional positive-pressure mechanical ventilation (CMV) for infants with severe respiratory failure because it allows adequate gas exchange at lower mean airway pressure (P aw ) than CMV, thus reducing lung injury. [2] [3] [4] [5] Elevated P aw in both CMV and HFOV has been shown to have no effect or to reduce cardiac output (CO) in animal models and humans. [6] [7] [8] [9] [10] [11] [12] [13] [14] Studies that have addressed the issue of CO in HFOV, specifically, report conflicting results. Some studies report no change in left ventricular output in animal models 13, 15, 16 and in children 17 when using P aw similar to CMV, while others suggest a decrease in CO during HFOV. [8] [9] [10] In preterm infants with respiratory distress syndrome (RDS), CO has been shown to be reduced significantly or unchanged during HFOV, but increased when HFOV is used to treat pulmonary interstitial emphysema. 19 More recently, Simma et al. 20 evaluated the hemodynamic effects of HFOV in 13 newborn term and preterm infants with RDS and a median gestational age and birthweight of 33 weeks and 2350 g, respectively. They reported a significant decrease in left ventricular CO secondary to reduced left ventricular filling and decreased contractility at higher P aw than CMV.
Seriously ill infants requiring HFOV often have proven or suspected pneumonia or systemic infection. Many clinicians use the synergistic combination of ampicillin and gentamicin for the empiric treatment of infections in these seriously ill, ventilated infants. The usual initial dose of gentamicin is 2.5 mg/kg every 12 hours for full-term infants, with doses adjusted based on serum gentamicin concentrations at steady state. We observed that infants receiving HFOV had higher trough serum gentamicin concentrations than that predicted by standard pharmacokinetic equations. 21 Persistent gentamicin trough concentrations greater than 2 mcg/ml have been associated with nephro-and ototoxicity. 22, 23 Gentamicin is eliminated almost entirely by the kidneys, and its clearance mimics that of serum creatinine. 24 Thus, it is important to avoid high serum trough concentrations and to provide for adequate monitoring of gentamicin therapy in newborn infants at risk for developing renal dysfunction from such treatments.
The purpose of this study was to compare pharmacokinetics of gentamicin from term newborn infants receiving HFOV to a matched control group of term newborn infants on CMV. We hypothesized that gentamicin elimination rate is reduced in patients receiving HFOV compared to CMV.
METHODOLOGY
This study was reviewed and approved by the Institutional Review Board and the requirement for patient consent was waived because of its retrospective nature. The study was a case-controlled design, examining full-term infants (Z37 weeks gestational age), who received HFOV between 1991 and 2001. Medical records were reviewed for full-term infants who were treated with HFOV or CMV and were also receiving gentamicin. In order to be included in the study, the infants were also required to have received at least four doses of gentamicin (2.5 mg/kg) each administered over 30 minutes, at prescribe internal prior to the determination of peak and trough serum concentrations. Infants were excluded from the study if they had congenital renal or cardiac anomalies, frank renal failure (defined as urine output less than 0.5 ml/kg/hour during the previous 24 hours, or a doubling of serum creatinine from baseline at the time of enrollment), asphyxia at birth, or inadequate sampling.
Each patient's medical record was reviewed and a standard data collection sheet was completed. Blood gas measurements and ventilator parameters (the highest and lowest values of PaO 2 and P aw ) were recorded for all patients for each day the patient received gentamicin, as well as continuously for a 3-hour window around the time the gentamicin peaks and troughs were drawn. The laboratory data included daily weights, blood urea nitrogen (BUN), serum creatinine (SCr), and urine output for gross evaluation of renal function. Gentamicin dosage, administration and sampling times, and values for peak and trough concentrations were also collected. Gentamicin administration and concentration measurement occurred according to a previously established protocol requiring infusion over 30 minutes and measurement of peak concentrations 30 minutes postinfusion. The trough concentration was drawn immediately prior to administration of the dose. These data were used to calculate pharmacokinetic parameters for each infant. If it was available, information regarding the infant's age at the start of gentamicin therapy, as well as other medications including the use of vasopressors was also recorded.
Based on the method of Neter et al., 25 to achieve power of 0.8 and an a error of 5%, this study would require 15 patients in each group to demonstrate a 20% difference in the clearance of gentamicin between the two groups.
DATA ANALYSIS
Pharmacokinetic analysis was performed using standard equations and the half-life (t 1/2 ), volume of distribution (V d ), elimination rate constant (K el ), and total body clearance (TBC) were calculated for each infant. Patient demographics and pharmacokinetic parameters are reported using descriptive statistics (mean±standard deviation) for each group of infants. The mean values for the four kinetic parameters (K el , t 1/2 , TBC, and V d ) and ventilator parameters (P aw ) were compared between the two groups of infants using the Student t-test. A p-value of less than 0.05 was required for significance.
RESULTS
The demographic characteristics of the 33 infants enrolled in this study are shown in Table 1 . The infants in both the groups had similar underlying conditions and the demographics were not statistically different except for gestational age. The postnatal age at treatment was higher for HFOV infants. The primary diagnoses of infants in both the groups were persistent pulmonary hypertension of the newborn, respiratory distress secondary to pneumonia, meconium aspiration syndrome or sepsis, or pneumothorax. One infant in the HFOV group had pulmonary hemorrhage. HFOV was initiated to improve gas exchange in infants who did not respond to conventional mechanical ventilation. Dopamine and dobutamine were used in all infants receiving HFOV and dopamine alone or in combination with dobutamine was used in 8/17 infants receiving CMV.
All infants were administered their first dose of gentamicin and were placed on mechanical ventilation at less than 24 hours of age. Renal function before and during therapy was therefore not compared, since it would not be expected to change in this time period. Renal function during treatment and gentamicin dosing patterns are reported in Table 2 . The mean gentamicin dose was 2.52±0.07 mg/kg/dose for CMV infants and 2.5±0.07 mg/kg/dose for HFOV infants. Initial dosing interval was 12 hours in all of the CMV infants and 13 of the 15 HFOV infants. The dosing interval for the remaining two HFOV infants was 18 hours. No patient in either group demonstrated oliguria (urine output <0.5 ml/kg/hour for 24 hours) prior to entry into the study; renal function during the course of the study was similar in the two groups.
The comparative pharmacokinetic parameters for CMV and HFOV patients are depicted in Table 3 . Statistical analysis using ttest for unequal variances yielded significant differences between the two groups with regard to K el , t 1/2 , TBC, as well as V d , with a p value of <0.05 for all comparisons. The mean of the highest P aw received by each patient in the HFOV group was 19.2±4.05 cmH 2 O, considerably higher than in the CMV group, which had a mean P aw of 13.4±2.23. These two means were not statistically significantly different (p>0.05).
DISCUSSION
We determined the pharmacokinetics of gentamicin in 33 term infants receiving either CMV or HFOV. The elimination rate constant, half-life, volume of distribution and clearance were all significantly different between these two groups indicating that HFOV alters gentamicin pharmacokinetics. The longer half-life of gentamicin requires prolongation of the dosing interval to reduce risk of toxicity. The HFOV infant group exhibited a slower elimination rate constant and a prolonged half-life, but they had a larger volume of distribution and a faster clearance. The hypothesized mechanism for altered pharmacokinetics during HFOV is reduced renal elimination of gentamicin, resulting in the increased half-life observed in the HFOV group. Prolonged K el and t 1/2 may reflect decreased cardiac output and renal blood flow with a consequent reduction in glomerular filtration rate (GFR). Decreased CO has been reported by some animal and human studies. [7] [8] [9] 14, [18] [19] [20] The issue remains controversial primarily because of varied underlying conditions, gestational age (premature vs full term animals or infants), and the P aw used at the time of studying the effects of HFOV on hemodynamics. When similar P aw was used during comparison of CO in HFOV and CMV, the effect on CO was similar. 13, 15 However, with a higher P aw used during HFOV, the CO is reduced. 18, 19 One could also speculate that the increase in clearance of gentamicin results from an increase in GFR as a compensatory mechanism. TBC is a product of V d and K el . Thus, an increase in either of these parameters could result in higher clearance as seen here with a larger V d in HFOV infants.
It is suggested that if the P aw is increased in patients on HFOV who have inadequate preload status, venous return may be impaired. 26 Fluid overload does not appear to be a consistent problem in infants who receive HFOV. However, one could theoretically argue that the increase in V d of gentamicin seen in our study may be a result of fluid treatment or altered hemodynamics during HFOV resulting in a larger total body fluid Patients who received HFOV were initially ventilated at higher mean airway pressure than infants who received CMV. Statistical comparison of the highest P aw in each group showed no significant difference in the mean values of P aw (p>0.05). However, since higher mean airway pressures have been associated with decreased cardiac output, this may be an important clinical mechanism for altering gentamicin clearance in patients who received HFOV.
Although we attempted to control for severity of illness by including only patients who received a full 7 to 10 course of gentamicin therapy, this factor cannot be excluded when interpreting the results of this study. Since infants who receive HFOV usually fail initial treatment with CMV, one could conclude that HFOV infants are likely to be more critically ill than infants receiving CMV. Indeed, many of these infants required high-dose pressors, nitric oxide treatment, neuromuscular blockade, and other therapeutic interventions. The mean serum creatinine was also higher in the HFOV group compared with CMV, although the difference did not achieve statistical significance. It is possible that some of the pharmacokinetic changes observed in this study were simply the result of a higher severity of illness in the HFOV infants. The postnatal age at treatment was higher in HFOV infants for two reasons. All infants in this group were first tried on CMV and then switched to HFOV. Also, accurate data on the exact timing of the first dose of gentamicin were not always available for infants transported from outside hospitals to our facility.
Based on these results, we recommend initiating treatment with gentamicin at 2.5 mg/kg every 18 hours in full-term infants receiving HFOV and closely monitoring serum gentamicin concentrations. Measurement of both peak and trough concentrations is necessary to determine effects on elimination and half-life of gentamicin and allow for prediction of patient-specific dosage regimens. The individualized dosing regimen must be reviewed periodically during the course of treatment and adjusted based on changes in renal function, if it occurs.
